Literature DB >> 2965162

Is atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat.

J E Greenwald1, M Sakata, M L Michener, S D Sides, P Needleman.   

Abstract

Atriopeptin (AP), a natriuretic-diuretic and vasodilatory peptide, is synthesized and secreted from mammalian atria. The definitive role of this peptide on cardiovascular physiology and pathophysiology has yet to be determined. We developed a population of autoimmune rats sensitized against their own AP to evaluate the consequences of prolonged AP deficiency on physiological and pathophysiological processes. Natriuresis in response to acute intravenous volume expansion was inhibited in the autoimmune rat, however, natriuresis produced by chronic oral salt loading was not suppressed in these animals. Plasma AP increased threefold in the spontaneously hypertensive rat when evaluated as a function of blood pressure. Immunization of these rats had no effect on the rate of development, magnitude of their developing hypertension, or their daily sodium excretion when compared with nonimmunized controls. Mineralocorticoid escape occurred during desoxycorticosterone acetate administration to rats. The ability of rats to escape from the sodium-retaining effects of this steroid was not affected by prior immunization against AP. These results suggest that AP is an important natriuretic substance in response to acute intravascular volume loading. However, atriopeptin does not appear to be involved in the natriuretic response to chronic intravascular volume loading, blood pressure regulation, or mineralocorticoid escape.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965162      PMCID: PMC329628          DOI: 10.1172/JCI113414

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  The tissue effects of mineralocorticoids.

Authors:  P J Mulrow; B H Forman
Journal:  Am J Med       Date:  1972-11       Impact factor: 4.965

2.  The amino acid sequence of an atrial peptide with potent diuretic and natriuretic properties.

Authors:  T G Flynn; M L de Bold; A J de Bold
Journal:  Biochem Biophys Res Commun       Date:  1983-12-28       Impact factor: 3.575

3.  Purification and sequence analysis of bioactive atrial peptides (atriopeptins).

Authors:  M G Currie; D M Geller; B R Cole; N R Siegel; K F Fok; S P Adams; S R Eubanks; G R Galluppi; P Needleman
Journal:  Science       Date:  1984-01-06       Impact factor: 47.728

4.  Atrial natriuretic factor in rat hypothalamus, atria and plasma: determination by specific radioimmunoassay.

Authors:  I Tanaka; K S Misono; T Inagami
Journal:  Biochem Biophys Res Commun       Date:  1984-10-30       Impact factor: 3.575

5.  Purification and complete amino acid sequence of beta-rat atrial natriuretic polypeptide (beta-rANP) of 5,000 daltons.

Authors:  K Kangawa; A Fukuda; N Minamino; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1984-03-30       Impact factor: 3.575

6.  Chronic infusion of low doses of atrial natriuretic factor (ANF Arg 101-Tyr 126) reduces blood pressure in conscious SHR without apparent changes in sodium excretion.

Authors:  R Garcia; G Thibault; J Gutkowska; K Horký; P Hamet; M Cantin; J Genest
Journal:  Proc Soc Exp Biol Med       Date:  1985-07

7.  Atrial natriuretic factor--a circulating hormone stimulated by volume loading.

Authors:  R E Lang; H Thölken; D Ganten; F C Luft; H Ruskoaho; T Unger
Journal:  Nature       Date:  1985 Mar 21-27       Impact factor: 49.962

8.  Monoclonal antibodies to human interferon-gamma. I. Antibodies to a synthetic carboxyl-terminal peptide.

Authors:  Y Ichimori; T Kurokawa; S Honda; N Suzuki; M Wakimasu; K Tsukamoto
Journal:  J Immunol Methods       Date:  1985-06-12       Impact factor: 2.303

9.  Development, validation and application of an enzyme immunoassay (EIA) of atriopeptin.

Authors:  L L McLaughlin; Y F Wei; P T Stockmann; K M Leahy; P Needleman; J Grassi; P Pradelles
Journal:  Biochem Biophys Res Commun       Date:  1987-04-14       Impact factor: 3.575

10.  Vasopressin-stimulated release of atriopeptin: endocrine antagonists in fluid homeostasis.

Authors:  P T Manning; D Schwartz; N C Katsube; S W Holmberg; P Needleman
Journal:  Science       Date:  1985-07-26       Impact factor: 47.728

View more
  6 in total

1.  Role of endogenous atrial natriuretic factor in acute congestive heart failure.

Authors:  M E Lee; W L Miller; B S Edwards; J C Burnett
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

2.  Chronic blockade of endogenous atrial natriuretic polypeptide (ANP) by monoclonal antibody against ANP accelerates the development of hypertension in spontaneously hypertensive and deoxycorticosterone acetate-salt-hypertensive rats.

Authors:  H Itoh; K Nakao; M Mukoyama; T Yamada; K Hosoda; G Shirakami; N Morii; A Sugawara; Y Saito; S Shiono
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon. Evidence for a guanylate cyclase-mediated pathway.

Authors:  N Yokota; B G Bruneau; M L Kuroski de Bold; A J de Bold
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

4.  Neural control of the endocrine rat heart.

Authors:  J H Jiao; A J Baertschi
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

5.  Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure.

Authors:  M Volpe; C Tritto; N De Luca; A F Mele; G Lembo; S Rubattu; M Romano; P De Campora; I Enea; B Ricciardelli
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

6.  Dietary sodium modulates mRNA abundance of enzymes involved in pituitary processing of proopiomelanocortin.

Authors:  G Chandramohan; X P Ni; J E Kalinyak; M H Humphreys
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.